ArticleBMJ open2021

Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study.

Nirosen Vijiaratnam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.